331 related articles for article (PubMed ID: 35380741)
1. PSMG3-AS1 enhances glioma resistance to temozolomide via stabilizing c-Myc in the nucleus.
Zhou L; Huang X; Zhang Y; Wang J; Li H; Huang H
Brain Behav; 2022 May; 12(5):e2531. PubMed ID: 35380741
[TBL] [Abstract][Full Text] [Related]
2. The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells.
Mazor G; Levin L; Picard D; Ahmadov U; Carén H; Borkhardt A; Reifenberger G; Leprivier G; Remke M; Rotblat B
Cell Death Dis; 2019 Mar; 10(3):246. PubMed ID: 30867410
[TBL] [Abstract][Full Text] [Related]
3. Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma.
Zhang Z; Yin J; Lu C; Wei Y; Zeng A; You Y
J Exp Clin Cancer Res; 2019 Apr; 38(1):166. PubMed ID: 30992025
[TBL] [Abstract][Full Text] [Related]
4. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G
J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of long noncoding RNA
Okamoto R; Toya K; Ogino Y; Sato A
Nucleosides Nucleotides Nucleic Acids; 2024; 43(1):86-98. PubMed ID: 37452786
[TBL] [Abstract][Full Text] [Related]
6. Lnc-TALC promotes O
Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C
Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733
[TBL] [Abstract][Full Text] [Related]
7. MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway.
Li C; Feng S; Chen L
Mol Cell Biochem; 2021 Feb; 476(2):699-713. PubMed ID: 33106913
[TBL] [Abstract][Full Text] [Related]
8. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
[TBL] [Abstract][Full Text] [Related]
9. NCK1-AS1 Increases Drug Resistance of Glioma Cells to Temozolomide by Modulating miR-137/
Chen M; Cheng Y; Yuan Z; Wang F; Yang L; Zhao H
Cancer Biother Radiopharm; 2020 Mar; 35(2):101-108. PubMed ID: 31750728
[No Abstract] [Full Text] [Related]
10. Implication of lncRNA ZBED3-AS1 downregulation in acquired resistance to Temozolomide and glycolysis in glioblastoma.
Dong J; Peng Y; Zhong M; Xie Z; Jiang Z; Wang K; Wu Y
Eur J Pharmacol; 2023 Jan; 938():175444. PubMed ID: 36462734
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic Forkhead box D3 antisense RNA 1 promotes cell survival and confers temozolomide resistance in glioblastoma cells through the miR-128-3p/WEE1 G2 checkpoint kinase axis.
Ling Z; Zhang J; Liu Q
Bioengineered; 2022 Mar; 13(3):6012-6023. PubMed ID: 35191808
[TBL] [Abstract][Full Text] [Related]
12. LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma.
Liu B; Zhou J; Wang C; Chi Y; Wei Q; Fu Z; Lian C; Huang Q; Liao C; Yang Z; Zeng H; Xu N; Guo H
Cell Death Dis; 2020 May; 11(5):384. PubMed ID: 32439916
[TBL] [Abstract][Full Text] [Related]
13. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
[TBL] [Abstract][Full Text] [Related]
14. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
[TBL] [Abstract][Full Text] [Related]
15. Long Noncoding RNA KCNQ1OT1 Confers Gliomas Resistance to Temozolomide and Enhances Cell Growth by Retrieving PIM1 From miR-761.
Wang W; Han S; Gao W; Feng Y; Li K; Wu D
Cell Mol Neurobiol; 2022 Apr; 42(3):695-708. PubMed ID: 32897512
[TBL] [Abstract][Full Text] [Related]
16. Silencing lncRNA LINC01410 suppresses cell viability yet promotes apoptosis and sensitivity to temozolomide in glioblastoma cells by inactivating PTEN/AKT pathway via targeting miR-370-3p.
Fu T; Yang Y; Mu Z; Sun R; Li X; Dong J
Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):680-692. PubMed ID: 34435542
[TBL] [Abstract][Full Text] [Related]
17. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma.
Lu C; Wei Y; Wang X; Zhang Z; Yin J; Li W; Chen L; Lyu X; Shi Z; Yan W; You Y
Mol Cancer; 2020 Feb; 19(1):28. PubMed ID: 32039732
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma.
Shang C; Tang W; Pan C; Hu X; Hong Y
Cancer Chemother Pharmacol; 2018 Apr; 81(4):671-678. PubMed ID: 29397407
[TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA-101 in glioblastoma.
Cai T; Liu Y; Xiao J
Cancer Med; 2018 Apr; 7(4):1404-1415. PubMed ID: 29479863
[TBL] [Abstract][Full Text] [Related]
20. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]